SCHEMBL16807809

SCHEMBL16807809

Cc1ccc2scc(C(C)C)c2c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
TRPA1 O75762 1/20 0.42
CHRM1 P11229 1/20 0.42
SLC6A2 P23975 1/20 0.42
ADRA1A P35348 1/20 0.42
HTR2B P41595 1/20 0.42
MAPT P10636 10/20 0.42
TP53 P04637 6/20 0.42
CA2 P00918 1/20 0.42
THRB P10828 2/20 0.41
USP2 O75604 1/20 0.41
CYP2A6 P11509 2/20 0.39
LDHA P00338 1/20 0.36
ALB P02768 1/20 0.36
LDHB P07195 1/20 0.36
ALOX5 P09917 1/20 0.33
CYP1A2 P05177 1/20 0.33
FFAR1 O14842 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15912347 0.81 FFAR1 (0.37) LMNATRPA1CYP2A6ALOX5FFAR1
SCHEMBL13197120 0.79 CYP2A6 (0.50) LMNAMAPTTP53CA2CYP2A6
SCHEMBL7476503 0.79 CYP2A6 (0.59) CA2CYP2A6
SCHEMBL25463642 0.79 MAPT (0.39) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL423281 0.75 CYP2A6 (0.64) LMNAMAPTTP53CA2THRB
SCHEMBL8343889 0.75 CA2 (0.39) LMNAMAPTTP53CA2THRB
SCHEMBL6599173 0.75 CA2 (0.42) LMNAMAPTTP53CA2THRB
SCHEMBL717441 0.74 ALOX5 (0.54) CHRM1SLC6A2MAPTCYP2A6ALOX5
SCHEMBL6608239 0.74 MAPT (0.46) LMNAMAPTTP53CA2THRB
SCHEMBL7541080 0.74 MAPT (0.45) LMNAMAPTTP53CA2THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022076831-A2 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. (US) 2022-04-14 WO disclosed
US-20160235748-A1 PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS GILEAD SCIENCES, INC. 2016-08-18 US disclosed
US-9278975-B2 Pyrazolo[1,5-A]pyrimidines as antiviral agents GILEAD SCIENCES, INC. (US) 2016-03-08 US disclosed
US-20150166546-A1 PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS GILEAD SCIENCES, INC. 2015-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166546-A1 PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS TYMP, ZC3HAV1, TYMS LMNA 3948/4885TRPA1 3903/4885CHRM1 3556/4885
US-20160235748-A1 PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS TYMP, ZC3HAV1, TYMS LMNA 3948/4885TRPA1 3903/4885CHRM1 3556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.